The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Antimicrobial Safety: Focus on Fluoroquinolones
Abstract
BACKGROUND/PURPOSE: Infrequent toxicities associated with certain drugs and drug classes have recently gained much attention from different health-care perspectives. To protect the patient, continued surveillance of safety and tolerability data is essential. Data from preclinical testing, phase 1-3 trials, and postmarketing surveillance may be used to objectively assess the risks associated with a specific drug or family of compounds. This review summarizes safety and tolerability data for the quinolones. MAIN FINDINGS: The most common adverse events associated with the quinolone class involve the gastrointestinal tract (nausea and diarrhea) and central nervous system (CNS) (headache and dizziness). These adverse events are usually mild and do not require discontinuation of therapy. Uncommon and potentially serious quinolone-related adverse events involve the cardiovascular system (rate-corrected electrocardiographic QT interval prolongation), musculoskeletal system (tendinitis and tendon rupture), endocrine system (glucose homeostasis dysregulation), renal system (crystalluria, interstitial nephritis, and acute renal failure), and the CNS (seizures). Severe idiosyncratic adverse events are specific to individual agents that may share some structural congruity, such as the 1-(2,4)-difluorophenyl group shared by trovafloxacin (associated with hepatitis), temafloxacin (associated with hemolytic-uremic syndrome), and tosufloxacin (associated with eosinophilic pneumonitis). Overall, discontinuation rates from clinical trials were <4% for the currently marketed quinolones. Quinolones with higher discontinuation rates, such as trovafloxacin (7.0%) and grepafloxacin (6.4%), are no longer available for general use. CONCLUSIONS: The currently marketed quinolones are well tolerated, with safety profiles similar to those of other antimicrobial classes. Although adverse effects are unusual, some, including tendinitis and CNS-related effects, are more common with quinolones than with other antimicrobial classes. Rare adverse effects attributed to some members of the quinolone family (e.g., Torsades de Pointes, hepatotoxicity, and dysglycemias) are more likely to occur in select "susceptible" populations. These adverse events can often be circumvented by avoiding exposure to the specific quinolone. In some cases, the therapeutic value offered by a quinolone may outweigh its potential risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia
Abbott, G. W., Sesti, F., Splawski, I., Buck, M. E., Lehmann, M. H., Timothy, K. W., Keating, M. T., & Goldstein, S. A. N. (1999) · Cell · doi:10.1016/s0092-8674(00)80728-x · Cited by 1,354
Nosocomial Acquisition of Clostridium difficile Infection
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y., & Stamm, W. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200402 · Cited by 1,326
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Structure-activity and structure-side-effect relationships for the quinolone antibacterials
Domagala, J. M. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.4.685 · Cited by 681
Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes
RODEN, D. M. (1998) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1998.tb00148.x · Cited by 667
Risk factors for Clostridium difficile infection
Bignardi, G. E. (1998) · Journal of Hospital Infection · doi:10.1016/s0195-6701(98)90019-6 · Cited by 647
Weinstein, R. A., & Hota, B. (2004) · Clinical Infectious Diseases · doi:10.1086/424667 · Cited by 635
Clostridium difficile–Associated Diarrhea
Johnson, S., & Gerding, D. N. (1998) · Clinical Infectious Diseases · doi:10.1086/520276 · Cited by 441
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Wilcox, M. H., Fawley, W. N., Wigglesworth, N., Parnell, P., Verity, P., & Freeman, J. (2003) · Journal of Hospital Infection · doi:10.1016/s0195-6701(02)00400-0 · Cited by 271
Gaynes, R., Rimland, D., Killum, E., Ken Lowery, H., Johnson II, T. M., Killgore, G., & Tenover, F. C. (2004) · Clinical Infectious Diseases · doi:10.1086/381551 · Cited by 251
Hypoglycemia as a Predictor of Mortality in Hospitalized Elderly Patients
Kagansky, N., Levy, S., Rimon, E., Cojocaru, L., Fridman, A., Ozer, Z., & Knobler, H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.15.1825 · Cited by 231
Pharmacodynamics of Fluoroquinolones
Lode, H., Borner, K., & Koeppe, P. (1998) · Clinical Infectious Diseases · doi:10.1086/514623 · Cited by 220
Quinolone Arthropathy in Animals Versus Children
Burkhardt, J. E., Walterspiel, J. N., & Schaad, U. B. (1997) · Clinical Infectious Diseases · doi:10.1086/516119 · Cited by 219
Fluoroquinolone antibacterials enhance UVA-induced skin tumors
Klecak, G., Urbach, F., & Urwyler, H. (1997) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/s1011-1344(96)07424-6 · Cited by 202
Fluoroquinolone Use and Clostridium difficile–associated Diarrhea
McCusker, M. E., Harris, A. D., Perencevich, E., & Roghmann, M.-C. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0906.020385 · Cited by 200
Gerding, D. N. (2004) · Clinical Infectious Diseases · doi:10.1086/382084 · Cited by 175
Clinical toxicological aspects of fluoroquinolones
Stahlmann, R. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(01)00509-4 · Cited by 173
Akahane, K., Sekiguchi, M., Une, T., & Osada, Y. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1704 · Cited by 159
Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use-safety report
HAMPEL, B., HULLMANN, R., & SCHMIDT, H. (1997) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199701000-00036 · Cited by 158
Temafloxacin Syndrome: Review of 95 Cases
Blum, M. D., Graham, D. J., & McCloskey, C. A. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.6.946 · Cited by 154
Shaffer, D., Singer, S., Korvick, J. A., & Honig, P. K. (2002) · Clinical Infectious Diseases · doi:10.1086/340861 · Cited by 151
QT Prolongation with Antimicrobial Agents: Understanding the Significance
Owens, R. C. (2004) · Drugs · doi:10.2165/00003495-200464100-00005 · Cited by 133
Self-citationAdverse Drug Reactions Related to the Use of Fluoroquinolone Antimicrobials
Leone, R., Venegoni, M., Motola, D., Moretti, U., Piazzetta, V., Cocci, A., Resi, D., Mozzo, F., Velo, G., Burzilleri, L., et al. (2003) · Drug Safety · doi:10.2165/00002018-200326020-00004 · Cited by 127
Torsades de Pointes Associated with Fluoroquinolones
Owens, R. C., & Ambrose, P. G. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.8.663.33201 · Cited by 111
Self-citationSettle, Wilcox, Fawley, Corrado, & Hawkey (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00428.x · Cited by 109
Quinolone Use as a Risk Factor for Nosocomial Clostridium difficile-Associated Diarrhea
Yip, C., Loeb, M. B., Salama, S. E., Moss, L., & Olde, J. (2001) · Infection Control and Hospital Epidemiology · doi:10.1086/501954 · Cited by 105
Ball, P. D., Stahlmann, R., Kubin, R., Choudhri, S., & Owens, R. C. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90170-1 · Cited by 102
Self-citationIncrease in insulin release from rat pancreatic islets by quinolone antibiotics
Maeda, N., Tamagawa, T., Niki, I., Miura, H., Ozawa, K., Watanabe, G., Nonogaki, K., Uemura, K., & Iguchi, A. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15201.x · Cited by 99
Risk Assessment for Antimicrobial Agent‐Induced QTc Interval Prolongation and Torsades de Pointes
Owens, R. C. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.3.301.34206 · Cited by 94
Self-citationHypoglycemia in Hospitalized Nondiabetic Older Patients
Shilo, S., Berezovsky, S., Friedlander, Y., & Sonnenblick, M. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb02752.x · Cited by 91
Chien, S., Chow, A. T., Natarajan, J., Williams, R. R., Wong, F. A., Rogge, M. C., & Nayak, R. K. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1562 · Cited by 87
Glyburide-ciprofloxacin interaction with resistant hypoglycemia
Roberge, R. J., Kaplan, R. M., Frank, R., et al. (2000) · Annals of Emergency Medicine · doi:10.1067/mem.2000.108617 · Cited by 87
Clinical pharmacodynamics of quinolones
Ambrose, P. G., Bhavnani, S. M., & Owens, R. C. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00061-8 · Cited by 82
Self-citationAdverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin
BOWIE, W. R., Willetts, V., & Jewesson, P. J. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1778 · Cited by 79
TOKURA, Y. (1998) · Journal of Dermatological Science · doi:10.1016/s0923-1811(98)00026-7 · Cited by 70
Gajjar, D. A., LaCreta, F. P., Kollia, G. D., Stolz, R. R., Berger, S., Smith, W. B., Swingle, M., & Grasela, D. M. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.8.76s.35182 · Cited by 69
Mathan, V. I., Wiederman, J., Dobkin, J. F., & Lindenbaum, J. (1989) · Gut · doi:10.1136/gut.30.7.971 · Cited by 62
Bertino, J., Owens, R. C., Carnes, T. D., & Iannini, P. B. (2002) · Clinical Infectious Diseases · doi:10.1086/339075 · Cited by 57
Self-citationAmbrose, P. G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg370 · Cited by 54
Self-citationMetabolism of Xenobiotics by Strains of Intestinal Bacteria
Soleim, H. A., & Scheline, R. R. (1972) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1972.tb03610.x · Cited by 43
Gavin, J. R., Kubin, R., Choudhri, S., Kubitza, D., Himmel, H., Gross, R., & Meyer, J. M. (2004) · Drug Safety · doi:10.2165/00002018-200427090-00005 · Cited by 41
Possible Gatifloxacin-Induced Hyperglycemia
Donaldson, A. R., Vandiver, J. R., & Finch, C. K. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d360 · Cited by 33
Pharmacokinetic-Pharmacodynamic Contributions to the Convulsant Activity of Fluoroquinolones in Rats
Delon, A., Bouquet, S., Huguet, F., et al. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1511 · Cited by 32
Bowie, W., Willetts, V., & Megran, D. W. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1774 · Cited by 26
Cited by
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Dorman, S. E., Nahid, P., Kurbatova, E. V., Phillips, P. P. J., Bryant, K., Dooley, K. E., Engle, M., Goldberg, S. V., Phan, H. T. T., Hakim, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033400 · Cited by 539
The Quinolones: Past, Present, and Future
Andriole, V. T. (2005) · Clinical Infectious Diseases · doi:10.1086/428051 · Cited by 428
Antibiotic-associated encephalopathy
Bhattacharyya, S., Darby, R. R., Raibagkar, P., Gonzalez Castro, L. N., & Berkowitz, A. L. (2016) · Neurology · doi:10.1212/wnl.0000000000002455 · Cited by 284
Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report
Riddle, M. S., Connor, B. A., Beeching, N. J., DuPont, H. L., Hamer, D. H., Kozarsky, P., Libman, M., Steffen, R., Taylor, D., Tribble, D. R., et al. (2017) · Journal of Travel Medicine · doi:10.1093/jtm/tax026 · Cited by 275
Metadata
- Authors
- Owens, R. C., & Ambrose, P. G.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-15
- Volume
- 41
- Issue
- Supplement_2
- Pages
- S144-S157
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2119524520
- Cited by
- 415
- References
- 45
- FWCI
- 22.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.